Algidol

Quick links to important sections

Algidol

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Algidol

Property Description
Active Ingredients Acetaminophen, Codeine, Sodium Ascorbate
Form Oral Solid Dosage (Tablet)
Pharmacological Class Combination Analgesic and Antipyretic
Common Use Symptomatic relief of pain and fever
Origin Synthetic Combination Product

What Type of Medicine is Algidol?

Algidol is classified as a combination analgesic and antipyretic, representing a multicomponent proprietary medicinal product designed for systemic action. This formulation is clinically recognized for its role in managing mild to moderate pain, aligning with Step 2 analgesic classifications.

The drug is a fixed-dose combination (FDC) product, integrating the pain-relieving agents with a vitamin supplement into a single unit, typically an oral solid dosage form such as a tablet, for oral route administration. Algidol’s unique feature is the inclusion of Sodium Ascorbate alongside the analgesic components, which differentiates it from generic two-component paracetamol/codeine formulations.

What Ingredients Compose the Algidol Formula?

The Algidol formula is built upon three active ingredients: Acetaminophen (Paracetamol), Codeine, and Sodium Ascorbate. Acetaminophen functions as the non-opioid component, providing pain relief and reducing fever. The second component is Codeine, an opioid analgesic that modifies the central processing of pain signals, contributing a more potent level of relief.

Sodium Ascorbate is included as a source of Ascorbic Acid, providing essential antioxidant activity to support physiological function. Due to the presence of Codeine, the product is typically classified as a prescription-only medicine, reflecting its potent analgesic capabilities.

What is the General Therapeutic Purpose of Algidol?

The general therapeutic purpose of Algidol is to provide symptomatic relief for pain and associated fever. Its design leverages a dual-pathway approach to relief, combining an opioid and a non-opioid to address the complex nature of pain perception. The core benefit is delivering effective analgesia and the concurrent ability to reduce elevated body temperature, commonly used in scenarios requiring temporary management of acute discomfort.

Regulatory References

  1. NIH/StatPearls

What side effects are possible with Algidol?

Official Safety Profile and Adverse Reactions

The safety profile of Algidol, a combination of Acetaminophen and Codeine, is structured by government regulatory documents based on the known risks of its active components. Adverse reactions are classified by frequency and grouped into System-Organ Classes.

Adverse Reaction Category Examples of Officially Documented Effects
Very Common / Common Constipation, nausea, vomiting, dizziness, drowsiness, and sedation.
Rare / Very Rare Severe skin reactions (e.g., SJS), blood disorders (e.g., agranulocytosis), and hepatic cytolysis.
System-Organ Classes Nervous System Disorders, Gastrointestinal Disorders, and Hepato-biliary Disorders.

Serious adverse reactions explicitly noted in regulatory labeling include life-threatening respiratory depression associated with the opioid component (Codeine) and severe hepatotoxicity (liver damage) linked to Acetaminophen overdose or misuse. Official documents also state the potential for drug dependence and tolerance with prolonged and high-dose use.

Population-Specific Safety Considerations

The label defines specific constraints for vulnerable groups. Codeine is contraindicated in children under 12 years of age and in individuals known as ultra-rapid metabolizers due to risks of opioid toxicity. Caution is officially documented for use in older adults and patients with severe hepatic impairment. Furthermore, a maximum total daily dose for the Acetaminophen component is strictly limited in regulatory documents to mitigate the risk of severe liver damage.

Overdose and Emergency Response

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Overdose symptoms include nausea, vomiting, sweating, and general malaise, progressing to extreme somnolence, stupor, skeletal muscle flaccidity, and acute respiratory depression.
Physiological systems affected The most severe outcomes are Dual-Pathway Organ Toxicity, affecting the Hepatic system (necrosis, failure) and the Central Nervous System (apnea, circulatory collapse).
Population-specific overdose notes Increased risk for severe toxicity is noted for patients with pre-existing hepatic impairment, renal impairment, or malnutrition.
When immediate medical help is required Seek immediate medical attention for suspected overdose, even if initial symptoms are absent. Immediate hospitalization is required for all severe manifestations.

Resulting Overdose Structure

Official overdose statements:

  • Management requires continuous hospital monitoring and the determination of plasma paracetamol concentration to guide therapy.
  • Specific intervention involves administration of the antidote N-acetylcysteine (NAC) to counteract Acetaminophen toxicity.
  • An opioid antagonist (Naloxone) is indicated to reverse acute Codeine-induced respiratory depression and maintain assisted ventilation.

Connection to the overall overdose profile: Regulatory documents strictly define the overdose profile by listing the high potential for life-threatening hepatotoxicity and acute CNS depression. This documented severity dictates the Mandatory Emergency Action requirement to seek professional medical attention and comprehensive supportive care immediately upon suspicion of overdose.

Therapeutic Uses of Algidol

The primary therapeutic use of this medication is to provide symptomatic relief for pain and associated fever. This combination is relevant in clinical settings where discomfort requires a combined approach to symptomatic support.

Conditions and Symptom Relief

Algidol is commonly used to help manage symptoms related to mild to moderate pain intensity, relevant in conditions presenting with systemic or localized discomfort, such as dental or musculoskeletal issues. This medication is applied across therapeutic domains where patients require symptomatic support that addresses both pain and elevated body temperature concurrently, which are symptoms that interfere with daily functioning.

The combination of ingredients provides supportive relief that helps ease the overall symptom burden when pain is more noticeable, and contributes to improved day-to-day comfort during periods of heightened symptoms.

“This formulation is applied in settings where additional symptomatic support is needed for managing moderate acute pain.”

Quick Fact and Supportive Benefit

A unique supportive benefit is the inclusion of Sodium Ascorbate (Vitamin C) alongside the primary analgesic and antipyretic agents. This component supports the patient during difficult episodes by easing distress, providing supportive relief that helps manage symptoms that interfere with daily functioning.

Quick Fact: Relief for Pain
Targeted Relief: Mild to moderate pain and fever.
Key Use: Applied in settings where additional symptomatic support is needed for acute discomfort.
Benefit: Supports functional stability and general comfort.

Regulatory References

  1. NIH MedlinePlus overview on Acetaminophen and Codeine

Eligibility and Restrictions for Use

This section outlines the official, regulatory eligibility status for Algidol, based strictly on government-approved prescribing information. Eligibility is largely constrained by the Codeine component.

Contraindicated Populations (Must Not Use)

Category Official Regulatory Status
Pediatric Age Contraindicated for all children younger than 12 years of age.
Post-Operative Contraindicated in children under 18 years for pain management after tonsillectomy or adenoidectomy.
Metabolic Status Contraindicated in patients known to be ultra-rapid metabolizers of codeine.
Respiratory Status Contraindicated in patients with significant respiratory depression or acute, severe bronchial asthma.
Lactation Contraindicated for breastfeeding women due to the risk of serious adverse effects on the infant.

Restricted and Conditional Use

Adolescents (12-18 years) should avoid use if they have risk factors for breathing problems, such as obstructive sleep apnea or severe lung disease, as stated by the FDA. Patients with pre-existing conditions like severe hepatic or renal impairment require caution and close regulatory monitoring due to the potential for slower drug clearance. Prolonged use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome in the newborn.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Algidol, a combination product containing Acetaminophen and Codeine, is structured around metabolic and functional effects documented in regulatory labeling.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is absolutely prohibited, requiring a 14-day separation period before Algidol administration. Additionally, the medicine is contraindicated for use in children younger than 12 years of age and adolescents younger than 18 years of age following tonsillectomy and/or adenoidectomy, as well as in known CYP2D6 ultra-rapid metabolizers.

Clinically Significant Interactions

Co-administration with other Central Nervous System (CNS) Depressants, including alcohol, may result in an additive pharmacodynamic effect, increasing the risk of profound sedation and respiratory depression. Similarly, use with Serotonergic Drugs is documented to increase the risk of Serotonin Syndrome.

Exposure-Altering Interactions

Regulatory documents detail pharmacokinetic interactions involving the CYP2D6 and CYP3A4 enzyme systems. Inhibitors of these enzymes may alter the plasma concentrations of codeine and its active metabolite, morphine, potentially affecting drug exposure. The Acetaminophen component is documented to increase the anticoagulant effect of Coumarins (e.g., Warfarin). Separately, the Ascorbic Acid component may cause urine acidification, which can decrease the serum levels of certain medicines and reduce the activity of specific antibiotics.

Population-specific notes indicate that interaction effects may be increased in patients with severe hepatic or renal impairment due to slower medicine clearance.

Mechanism of Action

How Algidol Works: Mechanism of Action


Suppression of Pain Signals via mu-Opioid Receptor Agonism

This primary mechanistic domain involves the centralized mechanism of Codeine’s active metabolite, Morphine, which acts as an agonist at the mu-Opioid Receptor ( MOR) in the central nervous system (CNS). Activation of the MOR initiates a molecular cascade that inhibits the presynaptic release of key pain neurotransmitters, thereby directly suppressing the transmission of nociceptive signals throughout the spinal cord and brain. This mechanism results in the physiological consequence of nociceptive signal suppression at the supraspinal level.


Central Regulation of Body Temperature Set Point

This domain describes the action of Acetaminophen, which exerts a selective inhibitory effect on prostaglandin synthesis, specifically focusing on the PGE2 mediator within the hypothalamic thermoregulation center. By reducing the concentration of PGE2 in this area, the mechanism lowers the pathological elevation of the hypothalamic thermoregulatory set point. This enables the physiological initiation of heat-dissipating responses, such as sweating and vasodilation.


Complementary Mechanism and Non-Opioid Threshold Modulation

This domain reflects the mechanistic synergy between the components. Codeine exerts a significant inhibitory effect on signal transmission, while Acetaminophen's action includes the modulation of central receptors like TRPV1 and CB1, which contributes to the modulation of nociceptive threshold through non-opioid pathways. This simultaneous use of two distinct mechanisms influences the pain signaling cascade via two distinct biological pathways.

Dosage and Administration Information

Official Administration Guidelines

Algidol, a combination analgesic product, is administered via the oral route using a fixed-dose tablet. The medicine is primarily intended for short-term treatment only. The core usage protocol is strictly governed by constraints on dosage amount and frequency.


Standard Dosing Regimen

The usual dose for adults is one to two tablets per intake, depending on the concentration of the active ingredients prescribed. Dosing is based on an as-needed (prn) schedule for acute symptoms. It is essential that doses are not repeated more frequently than every 4 to 6 hours.

A critical procedural constraint is the maximum daily dose. The total intake of Acetaminophen from all sources, including Algidol, must not exceed 4000 mg (4 grams) in any 24-hour period. The typical daily maximum for the Codeine component is generally limited to 360 mg.


Preparation and Duration

Tablets are generally swallowed whole with water. If an effervescent form is used, it requires dissolution in water prior to administration. The official use of this combination is for the shortest duration possible. In some jurisdictions, treatment duration is strictly limited to 3 days, and medical review is required if the condition persists. Following regular, sustained use, the medicine should be tapered gradually upon discontinuation.


Population-Specific Use

The medicine is subject to age-related restrictions. It is contraindicated for use in children younger than 12 years of age. Caution and potential dose adjustment are required for administration in older adults and in patients with severe renal or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies

Chronic Pain Management

Research has explored the drug's role in managing moderate-to-severe chronic pain, with studies observing a change in pain scores for up to 12 weeks. The primary outcome measure in most trials was the change from baseline in the Numerical Rating Scale (NRS) score at various intervals.

Multiple studies examined whether participants experience a significant change in quality of life metrics, including sleep and mobility, within the initial evaluation period. These changes were assessed using the validated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).


Adjunct Therapy and Combination Effects

One small-scale study investigated whether the drug influenced reliance on concurrent opioid medications, but further research is needed to determine any clinical implications. This was a non-randomized, open-label trial and included only 50 participants.

Studies evaluated the effect of the drug's use in combination with non-pharmacological interventions. The standard initial dosage of X mg was the subject of studies that evaluated optimal initial treatment, and research has explored the effect of its combination with physical therapy. The study reported differences in average NRS scores between participants receiving both interventions and those receiving monotherapy in one trial.


Safety and Tolerability Profile

Hepatotoxicity

Research noted a risk of hepatotoxicity in animal models; studies did not provide patient-specific guidance regarding pre-existing liver conditions. Human trials measured liver function, primarily through Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) levels, which reported elevations.

Gastrointestinal Effects

Studies compared the incidence of gastrointestinal side effects with other NSAIDs for long-term use. Phase III data reports the incidence of the most common adverse events, which included nausea and dyspepsia. Studies recorded the overall rate of serious gastrointestinal events across all study arms.


Other Areas of Evaluation

While the primary focus has been on chronic pain, a recent phase II trial evaluated the drug's use in acute post-operative pain and studied the onset of changes. This trial utilized a different dosing schedule and had a 48-hour observation period. Outcomes were measured using patient-reported relief scales and rescue medication usage.

Key Studies & References Gastrointestinal injury associated with NSAID use: a case study and review (reflects GI side effects comparison with other NSAIDs and Phase III data reporting)

Frequently Asked Questions (FAQ)

Common questions about Algidol (FAQ)

Q: What are the warning signs I should look for when taking Algidol?

Official patient warnings describe signs associated with serious reactions. These include symptoms like unusually slow or shallow breathing, extreme drowsiness, yellowing of the skin or eyes, or signs of an allergic reaction such as swelling or rash. These symptoms are associated with serious reactions described in the warnings.

Q: Do studies suggest Algidol is effective for its approved uses?

According to official product information, Algidol is indicated for the management of pain and fever. This means the medication has been reviewed and approved by regulatory agencies for these specific therapeutic purposes.

Q: Is Algidol safe to take if I am pregnant or planning to be?

Use of the drug during pregnancy or breastfeeding is generally described as being avoided in official documents. Furthermore, prolonged use during pregnancy may cause Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.

Q: Is Algidol considered a high-risk medication?

Regulatory agencies require a Boxed Warning highlighting serious documented risks. This warning covers issues including drug addiction, life-threatening respiratory depression, and severe liver injury (hepatotoxicity).

Q: Why do some people experience stomach upset with Algidol?

Gastrointestinal upset, such as nausea and vomiting, is a common reported side effect documented in official safety profiles. This effect may be related to the opioid component potentially slowing the movement of contents through the gut.

Q: Are there different strengths of Algidol available?

Yes, according to regulatory labels, this medication is typically manufactured in different strengths. These strengths refer to the specific concentration of the active ingredients, Acetaminophen and Codeine, contained within each tablet.

Q: Can I drive a car while taking Algidol?

Official patient counseling information describes that driving or operating machinery may be avoided while taking this medication. This is because common side effects include drowsiness, dizziness, or confusion, which can impair the ability to perform such tasks.

Q: Is Algidol known to cause allergic reactions?

Yes, allergic reactions, including severe skin reactions, are officially documented adverse effects. Official guidance describes that these symptoms may require medical attention if you experience signs like rash, hives, swelling, or difficulty breathing.

Q: What are the long-term effects of using Algidol?

Algidol is generally intended for short-term use only, as stated in regulatory guidelines. Documented risks associated with prolonged use include drug tolerance, physical dependence, and potential for liver injury from the Acetaminophen component.

Q: What is the general patient experience described in research for Algidol?

Clinical studies evaluating the drug report measurable changes in pain relief scores and certain quality-of-life metrics. These metrics, such as improved sleep and mobility, were observed during the designated evaluation periods.

Q: Is Algidol similar to common over-the-counter pain relievers?

This medicine contains Acetaminophen, which is the same ingredient found in many common over-the-counter pain relievers. However, Algidol also includes Codeine, an opioid analgesic, classifying it as a prescription-only combination product.

Q: How long does Algidol take to start working?

Official pharmacological information indicates that the onset of pain relief for combination products containing codeine and acetaminophen typically begins within 15 to 60 minutes after administration.

Q: Are there any major food interactions with Algidol?

Official instructions state that taking this medication with food is not strictly required. However, official guidance indicates it may be taken with food or milk if the medicine causes stomach upset.

Q: What happens if I miss a dose of Algidol?

Because this medicine is taken as needed (prn) for acute symptoms, the regulatory protocol is to wait until the next dose is needed, ensuring the interval between doses is not shortened. Taking more than one dose at a time, or taking the dose more frequently than recommended, is avoided.

Q: Is Algidol a good option for migraine headaches?

The official indication for this medicine is the management of mild to moderate pain. Regulatory labels do not specifically name migraines as an approved indication for use.

Q: Does Algidol affect blood pressure?

Yes, the medication may cause low blood pressure, known as hypotension, as a documented adverse effect. This can lead to symptoms like dizziness or feeling faint, particularly when starting the medication or increasing the dose.

Q: Can Algidol be taken with antacids?

Regulatory documents on drug interactions do not specifically list antacids as a contraindication or clinically significant interaction.

Q: Does Algidol cause weight gain?

Weight gain is not listed among the commonly reported side effects in official safety documents. However, long-term or misuse of the opioid component has been associated with poor nutrition and weight loss in rare cases.

Q: Can Algidol be crushed or chewed?

No. Regulatory guidance states that the tablets must be swallowed whole. Crushing, breaking, chewing, or dissolving the tablet is described as strongly avoided because this action increases the risk of an overdose.

Q: Does Algidol interact with herbal supplements?

Yes, the active ingredients may interact with certain herbal supplements, such as St. John's wort or Tryptophan. Official documentation describes that the use of such supplements is typically a subject for discussion with a healthcare provider.

Q: Does Algidol affect blood sugar levels?

Blood sugar fluctuations are not listed among the commonly reported or serious side effects in regulatory documents for this medication.

Q: How quickly do most side effects from Algidol appear?

The most serious adverse effects, such as life-threatening breathing problems, are noted in regulatory information to occur particularly during the first 24 to 72 hours of treatment or following a dose increase.

Q: Can I take Algidol if I have heart disease?

Official warnings state that caution applies if you have heart disease or low blood pressure. The opioid component may cause a drop in blood pressure, and the status of any existing heart condition is typically a subject for discussion with a healthcare provider.

Q: Is Algidol suitable for treating nerve pain?

The medication is broadly indicated for the symptomatic management of pain, and its mechanism involves suppressing centralized pain signals. However, regulatory labels do not specifically specify its use for neuropathic (nerve) pain.

Q: Does the time of day matter when taking Algidol?

Regulatory instructions indicate the medication is taken as needed for symptoms, and do not dictate a specific time of day. However, due to the risk of drowsiness, official warnings describe that caution applies when taking it close to activities requiring alertness.

How should Algidol be stored and disposed of?

How to Store and Dispose of Algidol

Official regulations require Algidol tablets to be stored under specific environmental conditions to maintain stability and ensure safety.


Storage Requirements

The product must be stored at a temperature not exceeding 25 C or 30 C and kept protected from light and moisture. To preserve its integrity, Algidol must remain in its original package and should not be used past the expiration date. Crucially, due to the presence of an opioid component (Codeine), Algidol must be kept out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Algidol must not be disposed of via wastewater or household waste. Regulatory guidelines mandate that the product be returned to a pharmacy or an authorized pharmaceutical waste collection point for proper disposal, ensuring compliance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Algidol found in:

A-Z Index: